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htahara syndrome and early myoclonic encephalopathy are the earliest presenting of the
pileptic encephalopathies. They are typically distinguished from each other according to
speciﬁc clinical and etiologic criteria. Nonetheless, considerable overlap exists between the
two syndromes in terms of clinical presentation, prognosis, and electroencephalographic
signature. Newer understandings of underlying etiologies of these conditionsmay support the
previously suggested concept that they represent a single spectrum of disease rather than two
distinct disorders. We review both syndromes, with particular focus on the underlying
genetics andpathophysiologyand implications regarding the classiﬁcationof these conditions.
 2012 Elsevier Inc. Open access under CC BY-NC-ND license.Introduction
Early myoclonic epilepsy and early infantile epileptic
encephalopathy (or Ohtahara syndrome) constitute the
earliest presenting of the age-dependent epileptic enceph-
alopathy syndromes. They are electroclinical syndromes,
deﬁned by their clinical features and electroencephalo-
graphic ﬁndings. They are classically distinguished from
each other according to their presentations and differing
etiologies, but they do share certain clinical, electroen-
cephalographic, and prognostic features. This review will
discuss the presentation, diagnosis, and pathogenesis of
these syndromes, with special consideration for new
understandings of pathophysiology and genetics, as well as
difﬁculties in differentiating between the two disorders.Historic background and classiﬁcation
In 1976, Ohtahara et al. described an epilepsy syndrome
affecting very young infants with characteristic electro-Dr. Beal; Department of
er; 111 East 210th Street;
C-ND license.encephalographic changes, and termed it “early infantile
epileptic encephalopathy with suppression-burst” [1].
Ohtahara further observed that this condition frequently
evolved intoWest syndrome and Lennox-Gastaut syndrome
[2]. The eponym Ohtahara syndrome, which is synonymous
with early infantile epileptic encephalopathy, came into
prominent use in the mid-1980s [3].
What came to be known as early myoclonic encepha-
lopathy was ﬁrst described 2 years after Ohtahara
syndrome, in 1978, in neonates with erratic myoclonus and
other seizure types [4]. Numerous terms have been applied
to this condition, including myoclonic epilepsy with
neonatal onset, neonatal epileptic encephalopathy with
periodic electroencephalogram bursts, and early myoclonic
epileptic encephalopathy [5].
In2001, theTaskForceonClassiﬁcationandTerminologyof
the International League Against Epilepsy included both
“Ohtahara syndrome” and “earlymyoclonic encephalopathy”
within the category of epileptic encephalopathies [6]. This
term describes epilepsy syndromes in which seizures and
epileptiform electroencephalographic abnormalities are
thought to contribute to progressive cerebral dysfunction.
Other syndromes in this group include West syndrome, Dra-
vet syndrome, Lennox-Gastaut syndrome, Landau-Kleffner
syndrome, and electrical status epilepticus during sleep.
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ﬁcation Commission of the International League Against
Epilepsy termed both Ohtahara syndrome and early
myoclonic encephalopathy as “electroclinical syndromes,”
characterized by their clinical and electroencephalographic
characteristics [7].
Clinical presentation
Ohtahara syndrome
Ohtahara syndrome presents in early infancy, within the
ﬁrst 3 months of age, and often within the ﬁrst 2 weeks [8].
Infants acutely develop tonic spasms that can be either
generalized or lateralized, can occur both singly or in clus-
ters, and are independent of the sleep cycle. Spasms typi-
cally last up to 10 seconds, and can occur hundreds of times
per day [9]. Approximately one third of patients with
Ohtahara syndrome will also develop other seizure types,
most commonly focal motor seizures, hemiconvulsions, or
generalized tonic-clonic seizures [10].
Electroencephalograms in Ohtahara syndrome indicate
a suppression burst pattern, comprising bursts of high-
amplitude spikes and polyspikes that alternate at
a regular rate with periods of electric suppression (Fig 1).
The bursts coincide with the tonic spasms [11]. The pattern
typically remains unchanged during both wakefulness and
sleep.
The prognosis is generally poor. Patients with Ohtahara
syndrome frequently die during infancy [10], and survivors
invariably manifest psychomotor impairments, whether or
not the seizures are ultimately controlled [5].
In some cases, Ohtahara syndrome can transition into
West syndrome over time, and can further evolve into
Lennox-Gastaut syndrome. In the series of Yamatogi and
Ohtahara, 75% of patients developed West syndrome
between 2 and 6 months of age, and 12% subsequently
developed Lennox-Gastaut syndrome [10]. The transition is
accompanied by changes in electroencephalographic
pattern. The evolution to West syndrome is marked by
a transition from suppression burst to hypsarhythmia, and
further progression to Lennox-Gastaut syndrome is accom-
panied by the development of a generalized, slow spike-Figure 1. Electroencephalogram indicates typical suppression burst pattern
encephalopathy. This recording is of a 3-month-old girl with Ohtahara syndromwave pattern. The close relationship among these three
syndromes has led to the theory that they represent age-
speciﬁc reactions in the brain to similar exogenous inﬂu-
ences, and to the proposal that they be classiﬁed together as
the age-dependent epileptic encephalopathies [2,8].
Early myoclonic encephalopathy
Considerable similarities characterize the clinical
presentations of Ohtahara syndrome and early myoclonic
encephalopathy. Like Ohtahara syndrome, early myoclonic
encephalopathy presents during the neonatal period,
usually within the ﬁrst 3 months of age, and sometimes as
early as a few hours after birth. The initial presentation
typically involves the onset of focal myoclonus, usually of
the face or extremities and or of only a small area, such as
a ﬁnger or eyelid. The jerks are often described as erratic or
fragmentary because they can shift from one area of the
body to another in an asynchronous, seemingly random
pattern.
Focal seizures are also very common, and occur in more
than 80% of cases [12]. These seizures may be overt,
involving deviation of an eye or tonic posturing, or theymay
be subtle, sometimes involving only autonomic signs such
as facial ﬂushing or apnea. Tonic spasms are also frequent,
occurring both singly and in clusters.
The key electroencephalographic feature in early
myoclonic encephalopathy comprises a suppression burst
pattern, much like that in Ohtahara syndrome (Fig 1). In the
case of early myoclonic encephalopathy, however, this
pattern is not continuous, and is often more distinct during
sleep. It was reported exclusively during sleep in 33% of
cases in one study [12]. The suppression burst pattern in
early myoclonic encephalopathy may not be appreciated at
disease onset, and follow-up electroencephalograms may
be necessary to arrive at the diagnosis [13]. The myoclonic
movements themselves are not associated with electro-
graphic changes.
The suppression burst pattern can evolve into an atypical
pattern of hypsarrhythmia in up to 50% of patients, typically
occurring at 3-5 months of age [12]. This change is generally
transient, lasting months, with a subsequent return to burst
suppression, which can last throughout childhood [14].that can be observed in both Ohtahara syndrome and early myoclonic
e. Time base, 30 mm/second; sensitivity, 10 mV/mm.
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patients die by 2 years of age [5]. The remainder manifest
severe psychomotor impairments, including some patients
who remain in a persistent vegetative state [15].
Etiology and pathogenesis
Ohtahara syndrome
Ohtahara syndrome can result fromavariety of etiologies,
but the majority of cases have been associated with struc-
tural brain abnormalities. Cases related to geneticmutations
and metabolic abnormalities have also been described,
although at least some of these cases also exhibited associ-
ated structural malformations. Even in some cases when no
structural lesion was evident on cranial imaging, post-
mortem examinations demonstrated evidence of a migra-
tion disorder or dysgenesis that was not previously
appreciated on neuroimaging [3,16].
Avarietyof structuralmalformationshavebeenassociated
with Ohtahara syndrome, including hemimegalencephaly
[11,17], agenesis of the corpus callosum [3,8], porencephaly
[8], agenesis of the mamillary bodies [18], and dentato-
olivary dysplasia [17]. Hypoxic injury [3], cortical dyspla-
sias, and cerebral migration disorders are also frequently
described [16,19,20].
Metabolic disorders that were reported to accompany
Ohtahara syndrome include nonketotic hyperglycinemia
[3], cytochrome C oxidase deﬁciency [21], pyridoxine
dependency, carnitine palmitoyltransferase deﬁciency [11],
and a case of Leigh encephalopathy [22]. More recently,
a patient with biotinidase deﬁciency [23] and two patients
with mitochondrial respiratory chain complex I deﬁciency
were described [24,25]. One of the patients with respiratory
chain complex I deﬁciency also manifested microcephaly,
thinning of the corpus callosum, and cortical atrophy [24].
The other patient with a similar complex 1 deﬁciency
demonstrated normal cranial imaging [25]. Deﬁciencies in
cytochrome C oxidase or respiratory chain complex I may
result in energy depletion during development, in turn
leading to demyelination and abnormalities in neuronal
migration [26].
Underlying genetic mutations have been increasingly
reported with Ohtahara syndrome. Mutations in the syn-
taxin binding protein 1 (STXBP1) gene, for example, have
been described in Ohtahara syndrome since 2008 [27]. A
proportion of patients with known Ohtahara syndrome is
now thought to manifest underlying STXBP1 mutations,
although the exact number of such patients has varied from
study to study, ranging from 10-13% [28,29] to 38% in the
original report [27]. Similarly, mutations of the Aristaless-
related homeobox (ARX) gene have also been associated
with Ohtahara syndrome [30-32]. In keeping with the close
relationship between the age-dependent epileptic
encephalopathies, mutations in both ARX and STXBP1 have
also been described in patients with West syndrome
[28,29,31]. Finally, two reports described patients with
Ohtahara syndrome who had mutations in the solute
carrier family 25 (SLC25A22) gene. Both patients were born
to consanguinous parents [33].
As with the metabolic disturbances, the mechanisms
by which these genetic abnormalities cause Ohtaharasyndrome are thought to be related to brain dysgenesis or
neuronal dysfunction. The SLC2A22 gene is involved in
mitochondrial glutamate transport. Mutations could lead to
energy depletion during development, or to neuronal
dysfunction and cell death [26]. The ARX gene plays a role in
regulating neuronal differentiation and proliferation, as
well as the migration of neuron progenitors to the devel-
oping cortex [26,34,35]. Mutations of the ARX gene have
been associated with structural abnormalities such as
hypoplastic corpus callosum, small basal ganglia and
hippocampi, a defect of the cavum septum pellucidum, and
cerebral atrophy [30-32]. Dysfunctional differentiation may
also lead to a deﬁciency of inhibitory interneurons, partly
accounting for the intractable seizures observed in these
patients [34]. The STXBP1 gene is involved in the regulation
of synaptic vesicle release, and thus, like ARX, also plays
a role in neuronal progenitor cell differentiation and
migration, because the release of g-aminobutyric acid and
glutamate are important for these functions [26,35].
Moreover, mutations of STXBP1 may lead to brainstem
abnormalities. Widespread cell death in the brainstem has
been observed in STXBP1 null mice [34]. Brainstem
dysfunction was previously implicated in Ohtahara
syndrome because the tonic seizures that are prevalent in
the syndrome are thought to be generated in the brainstem,
and brainstem abnormalities are frequently reported in
autopsies of patients with Ohtahara syndrome [36]. Inter-
estingly, brainstem dysfunction is also thought to
contribute to the development of hypsarrhythmia in
infantile spasms [37], and may play a role in the transition
from Ohtahara syndrome to West syndrome.
Early myoclonic encephalopathy
Similar to Ohtahara syndrome, the pathogenesis of early
myoclonic encephalopathy is variable, with structural,
metabolic, and genetic abnormalities all playing a role. The
overall picture in early myoclonic encephalopathy seems to
involve a diffuse process particularly involving the brain-
stem and white matter, possibly leading to deafferentation
and hyperexcitability of the cortex.
Unlike Ohtahara syndrome, focal structural abnormali-
ties are not frequently observed in early myoclonic
encephalopathy. However, progressive, diffuse cortical
atrophy has been reported in most cases [12]. Once again,
this ﬁnding is suggestive of an underlying metabolic or
degenerative disorder [9].
Associated metabolic abnormalities are frequently
described. In particular, nonketotic hyperglycinemia has
beenassociatedwitha largenumberof cases [38-40], and this
entitywas suggested toconstitute themost commonetiology
of earlymyoclonic encephalopathy [41]. Cases have also been
reported in association with D-glyceric acidemia, propionic
aciduria, molybdenum cofactor deﬁciency, pyridoxine deﬁ-
ciency, methylmalonic acidemia, sulﬁte oxidase deﬁciency,
Menkes disease, and Zellweger syndrome [39-44].
Pathologic ﬁndings in early myoclonic encephalopathy
include demyelination, multifocal spongy changes in the
white matter, imperfect lamination of the deep cortical
layers, perivascular concentric bodies, and astrocytic
proliferation [45]. Autopsy reports described prevalent
white matter abnormalities and brainstem pathology [36].
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white matter has also been reported, which is suggestive of
impaired neuronal migration and apoptosis [20].
Using functional neuroimaging techniques in a patient
with early myoclonic encephalopathy, Hirose et al. [46]
demonstrated hypoperfusion and hypometabolism in the
basal ganglia and thalami interictally, with ictal hyper-
perfusion of the basal ganglia, thalami, brainstem, and deep
front-parietal cortex. This ﬁnding was indicative of
dysfunction in these regions, and was thought to suggest
a functional deafferentation of the cortex from subcortical
structures [46].
A number of familial cases of early myoclonic encepha-
lopathy have been reported [14,40], raising the question of
whether the disease involves a genetic component. A likely
genetically mediated case was reported in association with
Schinzel-Giedion syndrome, a rare genetic multiple mal-
formation disorder [47]. In 2009, early myoclonic enceph-
alopathy was reported in associationwith a mutation of the
v-erb-a erythroblastic leukemia viral oncogene homologue
4 (ErbB4 gene), which is involved in the migration of
interneurons to the cortex [48]. This genetic abnormality is
consistent with the persistence of spiny neurons in the
white matter on pathologic examination, and of the func-
tional deafferentation described by Hirose et al. [46], both of
which seem to indicate impaired neuronal migration to the
cortex, suggesting a degree of “cortical isolation” in the
brains of these patients [20,46,48].
Assessment and treatment
The diagnosis of both Ohtahara syndrome and early
myoclonic encephalopathy is based on a typical clinical
picture and associated electroencephalographic ﬁndings, as
already described. The prognosis is universally poor. Neu-
roimaging to assess for structural brain abnormalities is
generally recommended in cases of Ohtahara syndrome.
Brainstem evoked potentials are occasionally abnormal in
both conditions, but normal studies do not exclude the
possibility of disease [36].
Only anecdotal evidence supports the use of speciﬁc
antiepileptic drugs in these conditions. Phenobarbital, val-
proate, pyridoxine, zonisamide, and benzodiazepines have
all demonstrated limited effectiveness in seizure control in
Ohtahara syndrome [10,49]. Adrenocorticotropic hormone
therapy also exerts limited efﬁcacy, and may be particularly
beneﬁcial in cases of Ohtahara syndrome that progress to
West syndrome [3,9]. None of the antiepileptic medicationsTable 1. Classic differentiation between Ohtahara syndrome and early myoclonic ep
Ohtahara Syndrome
EEG pattern Continuous suppression burst
Primary seizure type Tonic spasms
Other seizure types Focal motor seizures
Hemiconvulsions
Generalized tonic-clonic seizures
Major etiology Structural lesions
Evolution of disease 75% progress to West syndrome, 12% progress to
Gastaut syndrome
Abbreviation:
EEG ¼ Electroencephalogramhas been effective in treating early myoclonic encephalop-
athy, nor have alternative methods of seizure management
such as adrenocorticotropic hormone therapy, corticoste-
roids, and pyridoxine. Cases have been reported in which
the early myoclonic encephalopathy worsened after an
administration of vigabatrin [50]. Some success in control-
ling seizures has been reported with the ketogenic diet in
Ohtahara syndrome, but not in early myoclonic encepha-
lopathy [3,51].
The correction of underlying metabolic disorders may
lead to more favorable outcomes. In particular, patients
with Ohtahara syndrome have been reported to do rela-
tively well after the correction of underlying pyridoxine
deﬁciencies [11] or biotinidase deﬁciencies [23]. In cases of
early myoclonic encephalopathy associated with non-
ketotic hyperglycinemia, treatment with sodium benzoate,
ketamine, and dextromethorphan has been used, some-
times in combination with tryptophan, strychnine, or
imipramine [41,52,53]. These treatments can improve the
neonatal course, but do not seem to affect long-term
outcomes [53].
Cases with operable structural abnormalities such as
hemimegalencephaly or cortical dysplasia can beneﬁt from
neurosurgical intervention with focal resection or hemi-
spherectomy [54].
Differentiation
Earlymyoclonic encephalopathy and Ohtahara syndrome
sharemany features, including age at presentation, a similar
electroencephalographic pattern, intractable seizures, and
poor prognosis. Tonic seizures and focal motor seizures are
frequently observed in both syndromes. Thus differenti-
ating between the two conditions can be difﬁcult, especially
early in their course, and they have been conceptualized by
some as part of the same continuum of disease [34,36].
In 2006, Ohtahara and Yamatogi [9] highlighted the
differences between the syndromes, indicating that they
were separate and distinguishable diseases (Table 1).
Speciﬁcally, they pointed out the prevalence of structural
abnormalities in Ohtahara syndrome vs metabolic disease
in early myoclonic encephalopathy, and emphasized that
the suppression burst pattern is present equally in wake-
fulness and sleep in Ohtahara syndrome, whereas it is either
exclusively present during sleep or more distinct during
sleep in early myoclonic encephalopathy. Furthermore, the
evolution of disease can differ. Ohtahara syndrome can
progress to West syndrome and then to Lennox-Gastautilepsy
Early Myoclonic Encephalopathy
Discontinuous pattern, suppression burst not always
evident at ﬁrst, and often more distinct during sleep
Myoclonus
Focal motor seizures
Tonic spasms
Metabolic abnormalities
Lennox- Up to 50% develop transient atypical hypsarrhythmia, with
subsequent return to the suppression burst pattern
Table 2. Genetic mutations associated with epileptic encephalopathies
Mutation
Site
Ohtahara
Syndrome
EME West
Syndrome
SMEI Atypical RTT
with Early
Epilepsy
EFMR
ARX Yes Yes
CDKL5 Yes Yes
ErbB4 Yes
MAGI2 Yes
PCDH19 Yes Yes
PNKP Yes Yes
SCN1A Yes
SLC25 A22 Yes
STXBP1 Yes Yes
Abbreviations:
EFMR ¼ Epilepsy and mental retardation limited to females
EME ¼ Early myoclonic encephalopathy
RTT ¼ Rett syndrome
SMEI ¼ Severe myoclonic epilepsy of infancy (also known as Dravet syndrome)
Only epileptic encephalopathy syndromes presenting during infancy are included.
Some mutations may also be associated with other conditions, e.g., the SCN1A
mutation is associated with generalized epilepsy with febrile seizures.
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myoclonic encephalopathy typically remains unchanged for
years or transiently evolves to an atypical hypsarrhythmia
pattern, which is thought to differ signiﬁcantly from typical
West syndrome in terms of seizure type and atypical elec-
troencephalographic ﬁndings. Finally, Ohtahara and Yama-
togi [9] emphasized that although some seizure types do
overlap between the two syndromes, tonic spasms are the
ﬁrst seizure type observed in Ohtahara syndrome, whereas
focal seizures and erratic myoclonus occur ﬁrst in early
myoclonic encephalopathy [9].
Although these differences are helpful in differentiating
between the two conditions in their purest forms, consid-
erable clinical overlap may still occur in practice. As already
described, Ohtahara syndrome has been associated with
multiple metabolic disturbances in addition to structural
abnormalities. Furthermore, Schlumberger et al. reported
on several patients with Ohtahara syndrome in whom the
suppression burst pattern was not present equally in sleep
and wakefulness as expected, but was present only during
sleep or more marked during sleep [17]. The evolution of
disease can also be misleading, because the transient hyp-
sarrhythmia sometimes observed in early myoclonic
encephalopathy may be interpreted as indicating a transi-
tion toWest syndrome. Persistence of the suppression burst
pattern has been reported in Ohtahara syndrome, although
this persistence is generally thought to be more consistent
with the natural history of early myoclonic encephalopathy
[55]. Differences in seizure type may not help to differen-
tiate the two diseases, because tonic spasms and focal
motor seizures are a prominent feature of both.
Some authors proposed that the two syndromes may
actually involve one spectrum of disease, and that differ-
ences in seizure pattern reﬂect the differing progression of
pathology. In reviewing autopsy reports of patients with
Ohtahara syndrome and early myoclonic encephalopathy,
Djukic et al. [36] observed that brainstem pathologywas the
only consistent ﬁnding in every reported case. Brainstem
dysfunction was presumed to be the source of the tonic
seizures in these syndromes. Djukic et al. [36] hypothesized
that the brainstem dysfunction may occur earlier in Ohta-
hara syndrome, leading to early tonic seizures at presen-
tation. Brainstem involvement in early myoclonic
encephalopathy may be less severe initially but may prog-
ress over time, possibly as a result of a kindling process or
a release of the brainstem from cortical inhibitory control,
leading to the emergence of tonic seizures later in the
course of disease. Thus the differences between the two
syndromes may reﬂect disease burden in the brain, rather
than an indication that they are two separate entities [36].
Based on newer understandings of the genetics under-
lying these disorders, both syndromes were also postulated
to represent a “phenotypic continuum” in which multiple
underlying genetic abnormalities led to similar metabolic
and structural defects, producing a clinical spectrum of
disease [34]. Table 2 summarizes some prominent examples
of genetic and phenotypic overlap among the epileptic
encephalopathy syndromes. Many of these conditions can
be caused by multiple different genetic mutations, and
certain gene mutations can cause multiple syndromes. This
ﬁnding would indicate that differing underlying abnor-
malities can lead to common pathophysiologic pathways,resulting in a range of clinical phenotypes. In the case of
Ohtahara syndrome and early myoclonic encephalopathy,
both syndromes may result from processes leading to
impaired neuronal differentiation and migration, as already
described. Speciﬁcally, the ARX and STXBP1 mutations and
complex I deﬁciency associated with Ohtahara syndrome,
the ErbB4 mutation and multiple metabolic abnormalities
correlated with early myoclonic encephalopathy, and the
prominent brainstem pathology in both syndromes all
suggest a common pathophysiologic pathway leading to
abnormal neuronal migration and a functional isolation of
the cortex from the brainstem. Thus, multiple underlying
anomalies may lead to similar impairments in neuronal
differentiation and migration, resulting in a spectrum of
epileptic encephalopathies with clinical similarities that
encompasses Ohtahara syndrome and early myoclonic
encephalopathy.Conclusion
Ohtahara syndrome and early myoclonic encephalop-
athy, as electroclinical syndromes, are deﬁned by their
clinical presentations and speciﬁc electroencephalographic
ﬁndings. Based on these criteria, they are traditionally
distinguished from each other according to differing seizure
types, differences in their pattern of suppression burst, and
differing etiologies. Speciﬁcally, in its purest form, Ohtahara
syndrome is thought to result mostly from structural mal-
formations, whereas early myoclonic encephalopathy is
associated with metabolic abnormalities. However, consid-
erable clinical overlap between these conditions can occur.
Newer understandings of the genetic and pathophysio-
logic mechanisms underlying these diseases have revealed
further similarities between them. Broadly speaking, both
syndromes frequently seem associated with conditions that
lead to abnormal neuronal migration, possibly leading to
both structural brain abnormalities and a functional
disconnection between the cortex and the deep brain and
brainstem [20,26,34,46,48]. The prominence of brainstem
abnormalities in both syndromes similarly indicates
a disconnect between the cortex and subcortical structures.
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the intractable nature of the seizures as well the prevalence
of tonic seizures in both syndromes [34,36,46].
Thus, to think of Ohtahara syndrome and early myoclonic
encephalopathy as part of a spectrum may be possible. The
multiple etiologies identiﬁed in these conditions lead
to similar pathophysiologic pathways. These pathways
may result in a range of similar disease states involving
tonic seizures, a suppression burst electroencephalographic
pattern, onset during infancy, and progressive encephalop-
athywithpsychomotor retardation. The twosyndromesmay
therefore not involve two distinct diseases, but rather may
form part of a continuum of disease.
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